The Pharmacy Counter Is Breaking Your Benefits
Something is happening at the pharmacy counter. Patients are walking up, hearing a number, and walking away. No prescription filled. No therapy started. No one in the system any the wiser.
It is happening at scale. A study published this month by Buzz Health found that 49% of patients have previously walked away from a pharmacy counter without their medication because of cost. Nearly 6 in 10 reported being surprised by the price when they got there. And when out-of-pocket costs crossed $250, roughly 70% of patients did not start therapy at all.
Prescription abandonment is a structural failure that costs health plans, employers, clinical leaders, and benefits teams in ways that rarely show up in the same report. The cost compounds quietly, and by the time it surfaces, it is usually too late to reverse.
49% of patients have walked away from a pharmacy counter without their medication because of cost.
The Financial Blind Spot
For CFOs and finance leaders, pharmacy spend is visible. Abandonment is not. The connection between a prescription that was never filled in May and an emergency room visit in August does not appear in the same line item. That gap is where cost compounds without explanation.
Employers are already absorbing significant pressure on the front end. Employers project a median healthcare cost increase of 10% in 2026, according to the International Foundation of Employee Benefit Plans. Meanwhile, the KFF 2025 Employer Health Benefits Survey found that workers contributed an average of $6,850 toward family coverage costs last year, with total family premiums nearing $27,000. The downstream cost of abandoned therapy, avoidable hospitalization, and delayed care continues to accumulate in a column no one is watching.
The Buzz Health research identified another pattern worth noting: patients who have already paid full price toward a deductible are 13% less likely to fill prescriptions priced at $60 or more. High-deductible plan design, intended to control costs, can actively suppress the medication use the plan was designed to fund.
The Employee Experience Problem
For benefits and HR leaders, sticker shock at the pharmacy creates a specific kind of friction: the kind that shows up as complaints, escalations, and resentment weeks after a plan decision was made.
ACA premium subsidies expiring at the end of 2025 have already pushed roughly 1 in 10 ACA enrollees off their plans entirely, with that number expected to grow as first bills arrive. The members who remain are navigating higher deductibles, more complex cost-sharing structures, and less clarity about what things will cost. When a prescription runs over $300 and the lower-cost alternative requires a phone call no one told them to make, the benefit design is not the story they tell. The plan is.
Sticker shock does not resolve itself quietly. It erodes trust in the benefit, increases calls to HR, and generates a perception that the coverage does not work, whether or not it technically does.
Cost conversations occur in only about 30% of medical visits. The moment of surprise has been moved to the pharmacy counter, where it is too late to act.
The Clinical Reality
Physicians are closer to this problem than they realize. A Buzz Health survey of prescribers found that 76% say medication cost is a major or moderate barrier to patients starting or continuing treatment, yet most have limited insight into whether their prescriptions are ultimately filled. And research from the Society for Medical Decision Making found that physicians discuss medication costs with patients in only about 30% of visits. The moment of surprise has been moved to the pharmacy counter, where it is too late to act.
The clinical risk in abandonment is not theoretical. When patients do not start therapy, the downstream signals never appear in claims. The prescriber does not know the prescription was never filled. The health plan does not see a denial, only silence. Chronic disease progression, delayed therapy initiation, and avoidable readmissions accumulate in the space between a written prescription and a never-filled one.
Mental health medications and chronic disease therapies carry the highest abandonment risk. These are precisely the medications where early abandonment creates the longest tail of clinical consequence.
The Broker’s Dilemma
Brokers and consultants see abandonment as a client conversation waiting to happen. When outcomes fall short of projections, the question of why lands on the advisor. And the honest answer, that plan design systematically discourages the medication use it funds, is not a comfortable one to deliver.
The structural language is available and defensible: high cost-sharing creates predictable friction at the point of access. That friction suppresses utilization in ways that do not show up in pharmacy spend but do show up in medical claims and member satisfaction. Framing abandonment as a design consequence rather than a member behavior problem is both accurate and far easier for clients to hear.
The Fix Belongs at the Source
What the Buzz Health data makes clear, and what every layer of this problem confirms, is that the fix cannot live at the pharmacy counter. By the time a patient is standing there with a prescription they cannot afford, the opportunity to intervene has already passed.
The research is unambiguous on where intervention works: when physicians have visibility into the cost of the prescription and equivalent alternatives get considered. Patients do not walk away. The prescription that gets written is one the patient can affordably fill.
This insight isn’t new, but the system has yet to fully adopt a solution that works within standard practice. Physician-directed solutions that surface cost information within the existing prescribing workflow close the gap without adding steps, apps, or friction for patients who are already carrying enough.
The fix cannot live at the pharmacy counter. By the time a patient is standing there, the opportunity to intervene has already passed.
Abandonment is not a compliance issue. It is not a member behavior problem. It is a predictable outcome of a system that obscures cost information. Every stakeholder in the benefits chain absorbs part of that failure, and none of them can solve it alone.
The prescription that gets written and filled is the only one that does anything. Everything before and after it is the cost of getting there.
Call RazorMetrics today to help physicians close the cost gap for their patients.
